Biotech investors face a strategic decision between diversifying investments across numerous companies or concentrating their capital in a few industry giants. A comparison of three biotech ETFs—Invesco Nasdaq Biotechnology ETF (IBBQ), VanEck Biotech ETF (BBH), and Invesco Biotechnology & Genome ETF (PBE)—highlights differing expense ratios and yields. IBBQ has 251 holdings with the lowest expense ratio (0.19%) and a 0.80% yield, while BBH, with only 25 holdings, has a higher expense ratio (0.35%) and a lower yield (0.40%). PBE offers the highest yield (1.73%) but comes with the highest expense ratio (0.58%).
Despite its larger number of holdings, IBBQ shows greater concentration risk, with its top three positions making up 24% of assets. BBH’s concentration is even greater at 38%. Over five years, IBBQ has performed better than BBH due to risk mitigation from its larger portfolio, especially during market downturns. Factors such as GLP-1 competition and impending patent expirations are reshaping the sector, making fund selection crucial. For a balanced, low-cost option, IBBQ is recommended, while PBE may appeal to income-focused investors willing to accept more risk.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://finance.biggo.com/news/a299c7ad-ce3a-4224-a491-8b0a2e0d1b90
